RX Insider Trading
Insider Ownership Percentage: 33.65%
Insider Buying (Last 12 Months): C$0.00
Insider Selling (Last 12 Months): C$117,514.26
BioSyent Share Price & Price History
Current Price: C$15.97
Price Change: ▲ Price Increase of +0.09 (0.57%)
As of 09/4/2026 03:53 PM ET
BioSyent Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/28/2026 | Stephen Edwin William Wilton | Director | Sell | 805 | C$15.84 | C$12,751.20 | 7,876 | |
| 8/26/2026 | Peter Douglas Lockhard | Director | Sell | 246 | C$15.96 | C$3,926.16 | 176,935 | |
| 8/25/2026 | Peter Douglas Lockhard | Director | Sell | 200 | C$15.60 | C$3,120.00 | 177,181 | |
| 8/25/2026 | Peter Douglas Lockhard | Director | Sell | 300 | C$15.70 | C$4,710.00 | 177,381 | |
| 6/30/2026 | Seyed Ahmad Ashrafi | Director | Sell | 600 | C$14.50 | C$8,700.00 | 35,861 | |
| 6/30/2026 | Seyed Ahmad Ashrafi | Director | Sell | 800 | C$14.70 | C$11,760.00 | 36,461 | |
| 6/30/2026 | Seyed Ahmad Ashrafi | Director | Sell | 1,884 | C$14.65 | C$27,600.60 | 37,261 | |
| 6/22/2026 | Peter Douglas Lockhard | Director | Sell | 74 | C$14.00 | C$1,036.00 | 176,935 | |
| 6/18/2026 | Peter Douglas Lockhard | Director | Sell | 600 | C$14.00 | C$8,400.00 | 177,009 | |
| 5/28/2026 | Peter Douglas Lockhard | Director | Sell | 100 | C$14.05 | C$1,405.00 | 179,009 | |
| 5/26/2026 | Peter Douglas Lockhard | Director | Sell | 300 | C$14.10 | C$4,230.00 | 179,109 | |
| 3/30/2026 | Kevin Wilson | Insider | Sell | 1,912 | C$11.15 | C$21,318.80 | 61,058 | |
| 3/30/2026 | Neelu Atwal | Insider | Sell | 387 | C$14.50 | C$5,611.50 | 25,412 | |
| 3/30/2026 | Peter Douglas Lockhard | Director | Sell | 100 | C$14.70 | C$1,470.00 | 179,567 | |
| 3/26/2026 | Peter Douglas Lockhard | Director | Sell | 100 | C$14.75 | C$1,475.00 | 179,667 | |
| 5/22/2025 | Peter Douglas Lockhard | Director | Sell | 200 | C$11.75 | C$2,350.00 | | |
| 3/21/2025 | Peter Douglas Lockhard | Director | Sell | 40 | C$11.25 | C$450.00 | | |
| 3/18/2025 | Peter Douglas Lockhard | Director | Sell | 100 | C$11.25 | C$1,125.00 | | |
| 12/23/2024 | FAX Capital Corp. | Insider | Sell | 112,400 | C$11.28 | C$1,267,557.28 | | |
| 12/16/2024 | Seyed Ahmad Ashrafi | Director | Sell | 532 | C$12.02 | C$6,394.64 | | |
| 12/12/2024 | Robert Joseph March | Senior Officer | Sell | 4,775 | C$11.65 | C$55,628.75 | | |
| 11/25/2024 | Peter Douglas Lockhard | Director | Sell | 637 | C$11.45 | C$7,293.65 | | |
| 11/22/2024 | FAX Capital Corp. | Insider | Sell | 230,800 | C$11.12 | C$2,566,496.00 | | |
| 9/23/2024 | Peter Douglas Lockhard | Director | Sell | 600 | C$11.10 | C$6,660.00 | | |
| 9/20/2024 | Seyed Ahmad Ashrafi | Director | Sell | 2,320 | C$10.95 | C$25,404.00 | | |
| 7/23/2024 | FAX Capital Corp. | Insider | Sell | 500,000 | C$10.05 | C$5,025,000.00 | | |
| 6/28/2024 | Sharan Raghubir | Senior Officer | Sell | 423 | C$10.04 | C$4,246.92 | | |
| 6/20/2024 | Sharan Raghubir | Senior Officer | Sell | 1,755 | C$10.01 | C$17,566.50 | | |
| 6/12/2024 | Rene Goehrum | Director | Sell | 1,522 | C$9.38 | C$14,276.36 | | |
| 5/22/2024 | Peter Douglas Lockhard | Director | Sell | 432 | C$8.95 | C$3,866.40 | | |
| 4/29/2024 | BioSyent Inc. | Insider | Buy | 5,100 | C$8.55 | C$43,627.95 | | |
| 3/28/2024 | Larry Andrews | Director | Buy | 1,000 | C$8.70 | C$8,700.00 | | |
| 3/26/2024 | Peter Douglas Lockhard | Director | Sell | 600 | C$8.70 | C$5,220.00 | | |
| 11/27/2023 | Seyed Ahmad Ashrafi | Director | Sell | 1,000 | C$8.50 | C$8,500.00 | | |
| 4/13/2023 | FAX Capital Corp. | Insider | Sell | 65,000 | C$7.70 | C$500,500.00 | | |
SEC Filings (Institutional Ownership Changes) for BioSyent (CVE:RX)
11.79% of BioSyent stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis. In addition, the company provides Cathejell, a lubricant with anesthetic with the indication of lubricating and opening the urethra before the insertion of the catheter; Combogesic to manage mild to moderate acute pain and reduction of fever in adults; and Proktis-M, a rectal suppository for the healing of the anus and rectum. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006. BioSyent Inc. was founded in 2006 and is headquartered in Mississauga, Canada.
Read More on BioSyent
Today's Range
Now: C$15.97
Low: C$15.87
High: C$16.03
50 Day Range
MA: C$14.97
Low: C$14.42
High: C$16.00
52 Week Range
Now: C$15.97
Low: C$10.65
High: C$16.25
Volume
4,234 shs
Average Volume
7,986 shs
Market Capitalization
C$180.60 million
P/E Ratio
18.70
Dividend Yield
1.39%
Beta
1.110036
Who are the company insiders with the largest holdings of BioSyent?
BioSyent's top insider shareholders include:
- Blair Driscoll (Insider)
- Rene Christopher Goehrum (Director)
- Rene Christopher Goehrum (Insider)
- Peter Douglas Lockhard (Director)
- Kevin Wilson (Insider)
- Seyed Ahmad Ashrafi (Director)
- Neelu Atwal (Insider)
- Sara Elford (Director)
- Sharan Raghubir (Senior Officer)
- Stephen Edwin William Wilton (Director)
Learn More about top insider investors at BioSyent.